Research Analysts Set Expectations for ORIC FY2025 Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ORIC Pharmaceuticals in a research report issued on Thursday, May 29th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($1.71) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ORIC Pharmaceuticals’ current full-year earnings is ($2.17) per share.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.09.

Several other equities analysts have also recently issued reports on the company. Oppenheimer dropped their target price on ORIC Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. raised their target price on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Guggenheim reissued a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, May 5th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $19.17.

ORIC Pharmaceuticals Stock Up 3.6%

Shares of NASDAQ:ORIC opened at $8.26 on Monday. The company has a market cap of $587.19 million, a price-to-earnings ratio of -4.54 and a beta of 1.37. ORIC Pharmaceuticals has a fifty-two week low of $3.90 and a fifty-two week high of $14.67. The firm’s 50-day simple moving average is $5.38 and its 200-day simple moving average is $7.68.

Institutional Investors Weigh In On ORIC Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. grew its holdings in shares of ORIC Pharmaceuticals by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,963 shares of the company’s stock worth $121,000 after buying an additional 1,395 shares in the last quarter. Invesco Ltd. raised its holdings in ORIC Pharmaceuticals by 8.5% in the 4th quarter. Invesco Ltd. now owns 23,958 shares of the company’s stock valued at $193,000 after acquiring an additional 1,876 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in shares of ORIC Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock worth $109,000 after purchasing an additional 2,520 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of ORIC Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock worth $226,000 after purchasing an additional 3,131 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of ORIC Pharmaceuticals by 5.4% during the fourth quarter. Swiss National Bank now owns 62,400 shares of the company’s stock worth $504,000 after purchasing an additional 3,200 shares during the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.